Navigation Links
Reportlinker Adds Biomarkers - Technologies, Markets and Companies
Date:6/3/2010

p>

Innovative treatments for WNV 218

Western equine encephalitis 218

Sporadic virus epidemics 218

Coronavirus/severe acute respiratory syndrome 218

Therapeutic approaches to SARS 219

MAbs for SARS 219

siRNA treatment of SARS 220

Zoonotic viral infections 220

Vaccines for zoonotic viral diseases 220

Virus bioterrorism and biowarfare 221

Small pox as a biological weapon 221

Status of small pox vaccination 221

Strategies against virus bioterrorism and biowarfare 222

Increasing resistance by stimulating innate immune mechanisms 222

Nanoviricides for combating viral bioterrorism 223

Concluding remarks 223

12. Markets for Antivirals 225

Introduction 225

Markets according to disease 225

Influenza market 225

HIV/AIDS market 226

Hepatitis B and C markets 227

Markets according to products and approaches 227

Market values of monoclonal antibodies for viral diseases 227

Market values of vaccines for viral diseases 227

Markets for vaccines against HPV 228

Markets for other antiviral vaccines 228

Markets according to geographical areas 229

Geographical distribution of HIV/A
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Reportlinker Adds Future of Red Biotechnology in China
2. Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration
3. Reportlinker Adds the Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)
4. Reportlinker Adds SNP Genotyping and Analysis Markets
5. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
6. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
7. Reportlinker Adds Biotechnology Instrumentation - International Market Trends
8. Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective
9. Reportlinker Adds Pharmacodynamic Assays
10. Reportlinker Adds Neurostimulation - A Global Market Perspective
11. Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HONG KONG , July 31, 2015 ... "Company"), China,s leading provider of ... and stem cell storage services, today announced that the ... with the U.S. Securities and Exchange Commission. The filed ... year ended March 31, 2015. The Form 20-F can ...
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... on new patient data supporting the Ross heart, reconstruction procedure ... ... procedure, ATLANTA, Oct. 7 CryoLife, Inc. (NYSE: CRY ... surgeons from around the globe will participate in the,Ross Summit 2008, ...
... AMERIGROUP,Corporation (NYSE: AGP ) today announced ... quarter ended September 30, 2008, after the market ... Eastern Time on Thursday, October,23, 2008, AMERIGROUP,s management ... earnings and other information., To listen to ...
... to Save Millions of Lives, GERMANTOWN, Md., ... company focused on development of medical,countermeasures for biodefense ... a multiyear contract for advanced development of a,vaccine ... the National,Institute of Allergy and Infectious Diseases (NIAID), ...
Cached Biology Technology:CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 2CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 4AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 23 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 3
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... URBANA A new strategy to manage invasive species ... the Grand River Grasslands, an area within the North ... along with his colleagues at Iowa State and Oklahoma ... effort to establish a more diverse landscape for native ...
... 9, 2012More than half (52%) of the companies comprising ... revenue-generating, compared to about 21% four years ago, reports ... those companies, 31% have commercial products and 21% are ... to the current issue of GEN . ...
... July 11, and join a public forum with North ... Environmental Protection Agency Administrator Lisa P. Jackson, Canadian Environment ... Quesada. The webcast will kick off at 9 ... July 9 and 10 Joint Public Advisory Committee workshop ...
Cached Biology News:Grassroots approach to conservation developed 2Grassroots approach to conservation developed 3GEN reports on growth of tissue engineering revenues 2
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
... ZMD.414. Immunogen: Synthetic peptide derived from ... rat mTOR (Mammalian target of rapamycin FRAP ... human mTOR protein. On Western blots ... kDa. Reactivity: Human (positive control: HEK293 ...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
...
Biology Products: